Pharmaceutical developer Merck & Co. has gained approval for their latest cancer medication, pembrolizumab, from the U.S. Food and Drug Administration (FDA). Originally approved last week for the treatment of urothelial cancer, which is a form of bladder cancer, the scope of pembrolizumab has been expanded by the FDA.
Now, Merck & Co. has the green light to begin manufacturing and distributing pembrolizumab to help cancer patients who share a specific genetic marker. Merck & Co.’s pembrolizumab, also known as Keytruda, is a promising option for treating a wide variety of cancers.
A Whirlwind Week for Pembrolizumab and Merck & Co.
In a groundbreaking approval, the FDA has paved the way for the country’s first cancer medication that isn’t targeted at only one part of the body. In the past, Merck & Co. may not have been able to get the FDA to move further than allowing this treatment to be used by people with bladder cancer.
0 comments :
Post a Comment